nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CLCN2—Stimuli-sensing channels—ANO6—ankylosing spondylitis	0.191	0.526	CbGpPWpGaD
Lubiprostone—CLCN2—Ion channel transport—ANO6—ankylosing spondylitis	0.125	0.343	CbGpPWpGaD
Lubiprostone—Misoprostol—PTGER4—ankylosing spondylitis	0.11	0.781	CrCbGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.0434	0.12	CbGpPWpGaD
Lubiprostone—Dinoprostone—PTGER4—ankylosing spondylitis	0.0308	0.219	CrCbGaD
Lubiprostone—Blood potassium decreased—Methylprednisolone—ankylosing spondylitis	0.0158	0.0317	CcSEcCtD
Lubiprostone—Electrolyte imbalance—Methylprednisolone—ankylosing spondylitis	0.0143	0.0289	CcSEcCtD
Lubiprostone—Electrolyte imbalance—Betamethasone—ankylosing spondylitis	0.013	0.0263	CcSEcCtD
Lubiprostone—Electrolyte imbalance—Dexamethasone—ankylosing spondylitis	0.013	0.0263	CcSEcCtD
Lubiprostone—Blood potassium decreased—Prednisone—ankylosing spondylitis	0.0125	0.0251	CcSEcCtD
Lubiprostone—Abdominal distension—Prednisolone—ankylosing spondylitis	0.00412	0.00831	CcSEcCtD
Lubiprostone—Lethargy—Betamethasone—ankylosing spondylitis	0.00404	0.00813	CcSEcCtD
Lubiprostone—Lethargy—Dexamethasone—ankylosing spondylitis	0.00404	0.00813	CcSEcCtD
Lubiprostone—CBR1—Metabolism—B3GNT2—ankylosing spondylitis	0.00389	0.0107	CbGpPWpGaD
Lubiprostone—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.00384	0.00773	CcSEcCtD
Lubiprostone—Abdominal distension—Triamcinolone—ankylosing spondylitis	0.00379	0.00764	CcSEcCtD
Lubiprostone—Abdominal distension—Methylprednisolone—ankylosing spondylitis	0.00378	0.00762	CcSEcCtD
Lubiprostone—Influenza—Triamcinolone—ankylosing spondylitis	0.00377	0.00759	CcSEcCtD
Lubiprostone—Weight increased—Prednisolone—ankylosing spondylitis	0.00373	0.00751	CcSEcCtD
Lubiprostone—Lethargy—Prednisone—ankylosing spondylitis	0.00351	0.00708	CcSEcCtD
Lubiprostone—Weight increased—Triamcinolone—ankylosing spondylitis	0.00343	0.00691	CcSEcCtD
Lubiprostone—Weight increased—Methylprednisolone—ankylosing spondylitis	0.00342	0.00689	CcSEcCtD
Lubiprostone—Weight increased—Betamethasone—ankylosing spondylitis	0.00311	0.00627	CcSEcCtD
Lubiprostone—Weight increased—Dexamethasone—ankylosing spondylitis	0.00311	0.00627	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.00304	0.00612	CcSEcCtD
Lubiprostone—Abdominal distension—Prednisone—ankylosing spondylitis	0.003	0.00604	CcSEcCtD
Lubiprostone—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.00296	0.00595	CcSEcCtD
Lubiprostone—Lethargy—Methotrexate—ankylosing spondylitis	0.00294	0.00592	CcSEcCtD
Lubiprostone—Erythema—Prednisolone—ankylosing spondylitis	0.00285	0.00575	CcSEcCtD
Lubiprostone—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.00271	0.00546	CcSEcCtD
Lubiprostone—Weight increased—Prednisone—ankylosing spondylitis	0.00271	0.00546	CcSEcCtD
Lubiprostone—Ill-defined disorder—Prednisolone—ankylosing spondylitis	0.00265	0.00533	CcSEcCtD
Lubiprostone—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.00264	0.00531	CcSEcCtD
Lubiprostone—Erythema—Triamcinolone—ankylosing spondylitis	0.00262	0.00529	CcSEcCtD
Lubiprostone—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.00262	0.00528	CcSEcCtD
Lubiprostone—Erythema—Methylprednisolone—ankylosing spondylitis	0.00262	0.00528	CcSEcCtD
Lubiprostone—Malaise—Prednisolone—ankylosing spondylitis	0.00257	0.00518	CcSEcCtD
Lubiprostone—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.00257	0.00518	CcSEcCtD
Lubiprostone—Syncope—Prednisolone—ankylosing spondylitis	0.00256	0.00516	CcSEcCtD
Lubiprostone—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.00251	0.00505	CcSEcCtD
Lubiprostone—Ill-defined disorder—Triamcinolone—ankylosing spondylitis	0.00244	0.00491	CcSEcCtD
Lubiprostone—Ill-defined disorder—Methylprednisolone—ankylosing spondylitis	0.00243	0.00489	CcSEcCtD
Lubiprostone—Discomfort—Prednisolone—ankylosing spondylitis	0.0024	0.00484	CcSEcCtD
Lubiprostone—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.00238	0.0048	CcSEcCtD
Lubiprostone—Erythema—Betamethasone—ankylosing spondylitis	0.00238	0.0048	CcSEcCtD
Lubiprostone—Erythema—Dexamethasone—ankylosing spondylitis	0.00238	0.0048	CcSEcCtD
Lubiprostone—Malaise—Triamcinolone—ankylosing spondylitis	0.00237	0.00477	CcSEcCtD
Lubiprostone—Malaise—Methylprednisolone—ankylosing spondylitis	0.00236	0.00476	CcSEcCtD
Lubiprostone—Syncope—Triamcinolone—ankylosing spondylitis	0.00235	0.00474	CcSEcCtD
Lubiprostone—Syncope—Methylprednisolone—ankylosing spondylitis	0.00235	0.00473	CcSEcCtD
Lubiprostone—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.00234	0.00472	CcSEcCtD
Lubiprostone—Oedema—Prednisolone—ankylosing spondylitis	0.00233	0.00469	CcSEcCtD
Lubiprostone—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.00231	0.00465	CcSEcCtD
Lubiprostone—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.0023	0.00464	CcSEcCtD
Lubiprostone—Shock—Prednisolone—ankylosing spondylitis	0.00229	0.00462	CcSEcCtD
Lubiprostone—Cough—Triamcinolone—ankylosing spondylitis	0.00229	0.00461	CcSEcCtD
Lubiprostone—Tachycardia—Prednisolone—ankylosing spondylitis	0.00227	0.00458	CcSEcCtD
Lubiprostone—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.00225	0.00454	CcSEcCtD
Lubiprostone—Myalgia—Triamcinolone—ankylosing spondylitis	0.00223	0.0045	CcSEcCtD
Lubiprostone—Myalgia—Methylprednisolone—ankylosing spondylitis	0.00223	0.00449	CcSEcCtD
Lubiprostone—Anxiety—Methylprednisolone—ankylosing spondylitis	0.00222	0.00448	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.00221	0.00446	CcSEcCtD
Lubiprostone—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.00221	0.00445	CcSEcCtD
Lubiprostone—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.00221	0.00445	CcSEcCtD
Lubiprostone—Discomfort—Triamcinolone—ankylosing spondylitis	0.00221	0.00445	CcSEcCtD
Lubiprostone—Discomfort—Methylprednisolone—ankylosing spondylitis	0.0022	0.00444	CcSEcCtD
Lubiprostone—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00219	0.0044	CcSEcCtD
Lubiprostone—Malaise—Betamethasone—ankylosing spondylitis	0.00215	0.00433	CcSEcCtD
Lubiprostone—Malaise—Dexamethasone—ankylosing spondylitis	0.00215	0.00433	CcSEcCtD
Lubiprostone—Oedema—Triamcinolone—ankylosing spondylitis	0.00214	0.00431	CcSEcCtD
Lubiprostone—Syncope—Betamethasone—ankylosing spondylitis	0.00214	0.0043	CcSEcCtD
Lubiprostone—Syncope—Dexamethasone—ankylosing spondylitis	0.00214	0.0043	CcSEcCtD
Lubiprostone—Shock—Triamcinolone—ankylosing spondylitis	0.00211	0.00425	CcSEcCtD
Lubiprostone—Shock—Methylprednisolone—ankylosing spondylitis	0.0021	0.00424	CcSEcCtD
Lubiprostone—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.0021	0.00422	CcSEcCtD
Lubiprostone—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.00209	0.00422	CcSEcCtD
Lubiprostone—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.00209	0.00422	CcSEcCtD
Lubiprostone—Tachycardia—Triamcinolone—ankylosing spondylitis	0.00209	0.00421	CcSEcCtD
Lubiprostone—Mental disorder—Prednisone—ankylosing spondylitis	0.00209	0.0042	CcSEcCtD
Lubiprostone—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.00209	0.0042	CcSEcCtD
Lubiprostone—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00208	0.00418	CcSEcCtD
Lubiprostone—Erythema—Prednisone—ankylosing spondylitis	0.00207	0.00418	CcSEcCtD
Lubiprostone—Malnutrition—Prednisone—ankylosing spondylitis	0.00207	0.00418	CcSEcCtD
Lubiprostone—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.00207	0.00417	CcSEcCtD
Lubiprostone—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.00207	0.00416	CcSEcCtD
Lubiprostone—Myalgia—Dexamethasone—ankylosing spondylitis	0.00203	0.00408	CcSEcCtD
Lubiprostone—Myalgia—Betamethasone—ankylosing spondylitis	0.00203	0.00408	CcSEcCtD
Lubiprostone—Anxiety—Dexamethasone—ankylosing spondylitis	0.00202	0.00407	CcSEcCtD
Lubiprostone—Anxiety—Betamethasone—ankylosing spondylitis	0.00202	0.00407	CcSEcCtD
Lubiprostone—Discomfort—Betamethasone—ankylosing spondylitis	0.002	0.00404	CcSEcCtD
Lubiprostone—Discomfort—Dexamethasone—ankylosing spondylitis	0.002	0.00404	CcSEcCtD
Lubiprostone—Pain—Prednisolone—ankylosing spondylitis	0.00199	0.00401	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.00195	0.00393	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.00195	0.00392	CcSEcCtD
Lubiprostone—Oedema—Betamethasone—ankylosing spondylitis	0.00194	0.00392	CcSEcCtD
Lubiprostone—Oedema—Dexamethasone—ankylosing spondylitis	0.00194	0.00392	CcSEcCtD
Lubiprostone—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.00192	0.00388	CcSEcCtD
Lubiprostone—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.00192	0.00387	CcSEcCtD
Lubiprostone—Shock—Betamethasone—ankylosing spondylitis	0.00191	0.00385	CcSEcCtD
Lubiprostone—Shock—Dexamethasone—ankylosing spondylitis	0.00191	0.00385	CcSEcCtD
Lubiprostone—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.00191	0.00385	CcSEcCtD
Lubiprostone—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.00191	0.00384	CcSEcCtD
Lubiprostone—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.00191	0.00384	CcSEcCtD
Lubiprostone—Tachycardia—Betamethasone—ankylosing spondylitis	0.0019	0.00382	CcSEcCtD
Lubiprostone—Tachycardia—Dexamethasone—ankylosing spondylitis	0.0019	0.00382	CcSEcCtD
Lubiprostone—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.00189	0.0038	CcSEcCtD
Lubiprostone—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.00188	0.00379	CcSEcCtD
Lubiprostone—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.00188	0.00378	CcSEcCtD
Lubiprostone—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.00188	0.00378	CcSEcCtD
Lubiprostone—Malaise—Prednisone—ankylosing spondylitis	0.00187	0.00377	CcSEcCtD
Lubiprostone—Syncope—Prednisone—ankylosing spondylitis	0.00186	0.00375	CcSEcCtD
Lubiprostone—Anorexia—Dexamethasone—ankylosing spondylitis	0.00185	0.00373	CcSEcCtD
Lubiprostone—Anorexia—Betamethasone—ankylosing spondylitis	0.00185	0.00373	CcSEcCtD
Lubiprostone—Fatigue—Triamcinolone—ankylosing spondylitis	0.00185	0.00372	CcSEcCtD
Lubiprostone—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00184	0.00371	CcSEcCtD
Lubiprostone—Pain—Triamcinolone—ankylosing spondylitis	0.00183	0.00369	CcSEcCtD
Lubiprostone—Loss of consciousness—Prednisone—ankylosing spondylitis	0.00182	0.00367	CcSEcCtD
Lubiprostone—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.00179	0.00361	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.00177	0.00357	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.00177	0.00357	CcSEcCtD
Lubiprostone—Myalgia—Prednisone—ankylosing spondylitis	0.00177	0.00356	CcSEcCtD
Lubiprostone—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.00177	0.00356	CcSEcCtD
Lubiprostone—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.00176	0.00355	CcSEcCtD
Lubiprostone—Anxiety—Prednisone—ankylosing spondylitis	0.00176	0.00354	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.00175	0.00353	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.00175	0.00352	CcSEcCtD
Lubiprostone—Discomfort—Prednisone—ankylosing spondylitis	0.00174	0.00351	CcSEcCtD
Lubiprostone—Mental disorder—Methotrexate—ankylosing spondylitis	0.00174	0.00351	CcSEcCtD
Lubiprostone—Erythema—Methotrexate—ankylosing spondylitis	0.00173	0.00349	CcSEcCtD
Lubiprostone—Malnutrition—Methotrexate—ankylosing spondylitis	0.00173	0.00349	CcSEcCtD
Lubiprostone—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00172	0.00346	CcSEcCtD
Lubiprostone—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.00171	0.00345	CcSEcCtD
Lubiprostone—Dyspepsia—Betamethasone—ankylosing spondylitis	0.00171	0.00345	CcSEcCtD
Lubiprostone—Dysgeusia—Methotrexate—ankylosing spondylitis	0.0017	0.00342	CcSEcCtD
Lubiprostone—Oedema—Prednisone—ankylosing spondylitis	0.00169	0.00341	CcSEcCtD
Lubiprostone—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00169	0.0034	CcSEcCtD
Lubiprostone—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00169	0.0034	CcSEcCtD
Lubiprostone—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00169	0.0034	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.00168	0.00338	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.00168	0.00338	CcSEcCtD
Lubiprostone—Fatigue—Dexamethasone—ankylosing spondylitis	0.00168	0.00338	CcSEcCtD
Lubiprostone—Fatigue—Betamethasone—ankylosing spondylitis	0.00168	0.00338	CcSEcCtD
Lubiprostone—Shock—Prednisone—ankylosing spondylitis	0.00167	0.00335	CcSEcCtD
Lubiprostone—Pain—Betamethasone—ankylosing spondylitis	0.00166	0.00335	CcSEcCtD
Lubiprostone—Pain—Dexamethasone—ankylosing spondylitis	0.00166	0.00335	CcSEcCtD
Lubiprostone—Nervous system disorder—Prednisone—ankylosing spondylitis	0.00166	0.00334	CcSEcCtD
Lubiprostone—Tachycardia—Prednisone—ankylosing spondylitis	0.00165	0.00333	CcSEcCtD
Lubiprostone—Skin disorder—Prednisone—ankylosing spondylitis	0.00164	0.00331	CcSEcCtD
Lubiprostone—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.00164	0.0033	CcSEcCtD
Lubiprostone—Anorexia—Prednisone—ankylosing spondylitis	0.00161	0.00325	CcSEcCtD
Lubiprostone—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.00161	0.00324	CcSEcCtD
Lubiprostone—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.0016	0.00323	CcSEcCtD
Lubiprostone—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.0016	0.00323	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.00159	0.0032	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.00159	0.0032	CcSEcCtD
Lubiprostone—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.00158	0.00318	CcSEcCtD
Lubiprostone—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00157	0.00317	CcSEcCtD
Lubiprostone—Malaise—Methotrexate—ankylosing spondylitis	0.00156	0.00315	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.00154	0.00311	CcSEcCtD
Lubiprostone—Dizziness—Prednisolone—ankylosing spondylitis	0.00154	0.0031	CcSEcCtD
Lubiprostone—Asthenia—Triamcinolone—ankylosing spondylitis	0.00154	0.0031	CcSEcCtD
Lubiprostone—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00154	0.00309	CcSEcCtD
Lubiprostone—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00154	0.00309	CcSEcCtD
Lubiprostone—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00153	0.00309	CcSEcCtD
Lubiprostone—Cough—Methotrexate—ankylosing spondylitis	0.00151	0.00305	CcSEcCtD
Lubiprostone—Dyspepsia—Prednisone—ankylosing spondylitis	0.00149	0.003	CcSEcCtD
Lubiprostone—Chest pain—Methotrexate—ankylosing spondylitis	0.00148	0.00297	CcSEcCtD
Lubiprostone—Myalgia—Methotrexate—ankylosing spondylitis	0.00148	0.00297	CcSEcCtD
Lubiprostone—Decreased appetite—Prednisone—ankylosing spondylitis	0.00147	0.00296	CcSEcCtD
Lubiprostone—Rash—Prednisolone—ankylosing spondylitis	0.00147	0.00296	CcSEcCtD
Lubiprostone—Dermatitis—Prednisolone—ankylosing spondylitis	0.00147	0.00296	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.00147	0.00295	CcSEcCtD
Lubiprostone—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00146	0.00295	CcSEcCtD
Lubiprostone—Fatigue—Prednisone—ankylosing spondylitis	0.00146	0.00294	CcSEcCtD
Lubiprostone—Headache—Prednisolone—ankylosing spondylitis	0.00146	0.00294	CcSEcCtD
Lubiprostone—Discomfort—Methotrexate—ankylosing spondylitis	0.00146	0.00294	CcSEcCtD
Lubiprostone—Constipation—Prednisone—ankylosing spondylitis	0.00145	0.00292	CcSEcCtD
Lubiprostone—Dizziness—Triamcinolone—ankylosing spondylitis	0.00142	0.00285	CcSEcCtD
Lubiprostone—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00141	0.00285	CcSEcCtD
Lubiprostone—Feeling abnormal—Prednisone—ankylosing spondylitis	0.00139	0.00281	CcSEcCtD
Lubiprostone—Asthenia—Betamethasone—ankylosing spondylitis	0.00139	0.00281	CcSEcCtD
Lubiprostone—Asthenia—Dexamethasone—ankylosing spondylitis	0.00139	0.00281	CcSEcCtD
Lubiprostone—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00139	0.00279	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.00138	0.00279	CcSEcCtD
Lubiprostone—Nausea—Prednisolone—ankylosing spondylitis	0.00138	0.00279	CcSEcCtD
Lubiprostone—Skin disorder—Methotrexate—ankylosing spondylitis	0.00137	0.00277	CcSEcCtD
Lubiprostone—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.00137	0.00275	CcSEcCtD
Lubiprostone—Vomiting—Triamcinolone—ankylosing spondylitis	0.00136	0.00274	CcSEcCtD
Lubiprostone—Vomiting—Methylprednisolone—ankylosing spondylitis	0.00136	0.00274	CcSEcCtD
Lubiprostone—Rash—Triamcinolone—ankylosing spondylitis	0.00135	0.00272	CcSEcCtD
Lubiprostone—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00135	0.00272	CcSEcCtD
Lubiprostone—Anorexia—Methotrexate—ankylosing spondylitis	0.00135	0.00272	CcSEcCtD
Lubiprostone—Rash—Methylprednisolone—ankylosing spondylitis	0.00135	0.00271	CcSEcCtD
Lubiprostone—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.00135	0.00271	CcSEcCtD
Lubiprostone—Headache—Triamcinolone—ankylosing spondylitis	0.00134	0.0027	CcSEcCtD
Lubiprostone—Headache—Methylprednisolone—ankylosing spondylitis	0.00134	0.0027	CcSEcCtD
Lubiprostone—Abdominal pain—Prednisone—ankylosing spondylitis	0.00134	0.0027	CcSEcCtD
Lubiprostone—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00133	0.00268	CcSEcCtD
Lubiprostone—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00133	0.00268	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.00129	0.0026	CcSEcCtD
Lubiprostone—Dizziness—Dexamethasone—ankylosing spondylitis	0.00129	0.00259	CcSEcCtD
Lubiprostone—Dizziness—Betamethasone—ankylosing spondylitis	0.00129	0.00259	CcSEcCtD
Lubiprostone—Nausea—Triamcinolone—ankylosing spondylitis	0.00127	0.00256	CcSEcCtD
Lubiprostone—Nausea—Methylprednisolone—ankylosing spondylitis	0.00127	0.00256	CcSEcCtD
Lubiprostone—Dyspnoea—Methotrexate—ankylosing spondylitis	0.00126	0.00254	CcSEcCtD
Lubiprostone—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00125	0.00251	CcSEcCtD
Lubiprostone—Dyspepsia—Methotrexate—ankylosing spondylitis	0.00125	0.00251	CcSEcCtD
Lubiprostone—Vomiting—Betamethasone—ankylosing spondylitis	0.00124	0.00249	CcSEcCtD
Lubiprostone—Vomiting—Dexamethasone—ankylosing spondylitis	0.00124	0.00249	CcSEcCtD
Lubiprostone—Decreased appetite—Methotrexate—ankylosing spondylitis	0.00123	0.00248	CcSEcCtD
Lubiprostone—Rash—Dexamethasone—ankylosing spondylitis	0.00123	0.00247	CcSEcCtD
Lubiprostone—Rash—Betamethasone—ankylosing spondylitis	0.00123	0.00247	CcSEcCtD
Lubiprostone—Dermatitis—Dexamethasone—ankylosing spondylitis	0.00122	0.00247	CcSEcCtD
Lubiprostone—Dermatitis—Betamethasone—ankylosing spondylitis	0.00122	0.00247	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.00122	0.00246	CcSEcCtD
Lubiprostone—Fatigue—Methotrexate—ankylosing spondylitis	0.00122	0.00246	CcSEcCtD
Lubiprostone—Headache—Betamethasone—ankylosing spondylitis	0.00122	0.00245	CcSEcCtD
Lubiprostone—Headache—Dexamethasone—ankylosing spondylitis	0.00122	0.00245	CcSEcCtD
Lubiprostone—Asthenia—Prednisone—ankylosing spondylitis	0.00121	0.00245	CcSEcCtD
Lubiprostone—Pain—Methotrexate—ankylosing spondylitis	0.00121	0.00244	CcSEcCtD
Lubiprostone—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.00117	0.00235	CcSEcCtD
Lubiprostone—Diarrhoea—Prednisone—ankylosing spondylitis	0.00116	0.00233	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.00116	0.00233	CcSEcCtD
Lubiprostone—Nausea—Dexamethasone—ankylosing spondylitis	0.00115	0.00233	CcSEcCtD
Lubiprostone—Nausea—Betamethasone—ankylosing spondylitis	0.00115	0.00233	CcSEcCtD
Lubiprostone—Dizziness—Prednisone—ankylosing spondylitis	0.00112	0.00225	CcSEcCtD
Lubiprostone—Abdominal pain—Methotrexate—ankylosing spondylitis	0.00112	0.00225	CcSEcCtD
Lubiprostone—Vomiting—Prednisone—ankylosing spondylitis	0.00108	0.00217	CcSEcCtD
Lubiprostone—Rash—Prednisone—ankylosing spondylitis	0.00107	0.00215	CcSEcCtD
Lubiprostone—Dermatitis—Prednisone—ankylosing spondylitis	0.00107	0.00215	CcSEcCtD
Lubiprostone—Headache—Prednisone—ankylosing spondylitis	0.00106	0.00214	CcSEcCtD
Lubiprostone—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.00104	0.0021	CcSEcCtD
Lubiprostone—Asthenia—Methotrexate—ankylosing spondylitis	0.00101	0.00204	CcSEcCtD
Lubiprostone—Nausea—Prednisone—ankylosing spondylitis	0.00101	0.00203	CcSEcCtD
Lubiprostone—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000968	0.00195	CcSEcCtD
Lubiprostone—Dizziness—Methotrexate—ankylosing spondylitis	0.000935	0.00188	CcSEcCtD
Lubiprostone—Vomiting—Methotrexate—ankylosing spondylitis	0.000899	0.00181	CcSEcCtD
Lubiprostone—Rash—Methotrexate—ankylosing spondylitis	0.000892	0.0018	CcSEcCtD
Lubiprostone—Dermatitis—Methotrexate—ankylosing spondylitis	0.000891	0.00179	CcSEcCtD
Lubiprostone—Headache—Methotrexate—ankylosing spondylitis	0.000886	0.00179	CcSEcCtD
Lubiprostone—Nausea—Methotrexate—ankylosing spondylitis	0.00084	0.00169	CcSEcCtD
